Wall Street analysts expect AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to announce earnings per share (EPS) of ($0.21) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for AcelRx Pharmaceuticals’ earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.25). AcelRx Pharmaceuticals also reported earnings per share of ($0.21) during the same quarter last year. The business is scheduled to issue its next quarterly earnings results on Thursday, March 1st.

On average, analysts expect that AcelRx Pharmaceuticals will report full-year earnings of ($1.10) per share for the current fiscal year, with EPS estimates ranging from ($1.18) to ($0.99). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.95) per share, with EPS estimates ranging from ($1.14) to ($0.70). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for AcelRx Pharmaceuticals.

A number of research firms recently commented on ACRX. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of AcelRx Pharmaceuticals in a report on Tuesday, October 3rd. Roth Capital set a $8.00 price target on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 12th. Piper Jaffray Companies set a $3.00 price target on shares of AcelRx Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, July 25th. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Finally, Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. AcelRx Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $6.83.

AcelRx Pharmaceuticals (NASDAQ ACRX) traded down $0.08 during midday trading on Tuesday, hitting $1.90. 682,100 shares of the company were exchanged, compared to its average volume of 1,002,892. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78. AcelRx Pharmaceuticals has a twelve month low of $1.55 and a twelve month high of $5.75.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect AcelRx Pharmaceuticals, Inc. (ACRX) Will Announce Earnings of -$0.21 Per Share” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/14/brokerages-expect-acelrx-pharmaceuticals-inc-acrx-will-announce-earnings-of-0-21-per-share.html.

In related news, insider Pamela P. Palmer acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average cost of $2.95 per share, with a total value of $29,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vincent J. Angotti acquired 15,000 shares of the stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $45,000.00. Following the completion of the transaction, the chief executive officer now directly owns 15,000 shares of the company’s stock, valued at approximately $45,000. The disclosure for this purchase can be found here. Insiders have bought 42,000 shares of company stock worth $121,980 in the last 90 days. 28.10% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in ACRX. Perennial Advisors LLC purchased a new position in AcelRx Pharmaceuticals during the third quarter valued at approximately $138,000. Virtu KCG Holdings LLC grew its position in AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after purchasing an additional 101,742 shares in the last quarter. LMR Partners LLP purchased a new position in AcelRx Pharmaceuticals during the second quarter valued at approximately $319,000. Bank of New York Mellon Corp grew its position in AcelRx Pharmaceuticals by 6.6% during the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after purchasing an additional 6,942 shares in the last quarter. Finally, WealthTrust Axiom LLC grew its position in AcelRx Pharmaceuticals by 50.0% during the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after purchasing an additional 70,000 shares in the last quarter. 23.09% of the stock is currently owned by hedge funds and other institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.